MedTrace Logo

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

NCT07290270 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2026-03-30

No results posted yet for this study

Summary

This non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical outcomes, real-world characteristics, and quality of life during the treatment period and up to one year after treatment completion.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-04
Primary Completion
2029-08-31
Completion
2029-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07290270 on ClinicalTrials.gov